DUBLIN, January 24, 2023 /PRNewswire/ — The report “Hepatitis C Testing Market by Technique, By Test, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031” has been added to from ResearchAndMarkets.com offer.
Global Hepatitis C Testing Market was valued at $1,329.0 million in 2021, and should reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.
Hepatitis C is a viral infection that causes inflammation of the liver, sometimes leading to severe liver damage. The hepatitis C virus (HCV) is spread through contaminated blood. Hepatitis C can be diagnosed with an antibody test, genotype test, and viral load test.
Rising rate of hepatitis C and increased awareness of hepatitis C is driving the growth of the market. For example, according to a World Health Organization (WHO) report published on June 2022, worldwide, an estimated 58 million people are chronically infected with the hepatitis C virus, with approximately 1.5 million new infections occurring each year. An estimated 3.2 million adolescents and children are infected with chronic hepatitis C. Thus, increasing prevalence of Hepatitis C globally is driving the growth of the market.
Moreover, factors such as increase in blood donation and increase in blood transfusion rate are driving the growth of the market. Blood transfusion is one of the main causes of transmission of the hepatitis C virus.
For example, according to the report of the World Health Organization (WHO) published on May 2022, approximately 118.54 million blood donations are made worldwide. 40% of them are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations be screened for infections before use. Screening for HIV, hepatitis B, hepatitis C and syphilis should be mandatory.
Additionally, increased R&D activities for the development of advanced hepatitis C tests such as immunoassay and polymerase chain reaction (PCR), increased Food & Drug Administration (FDA ) American and new product launch in the market by key players is driving the growth of the market. .
For example, in December 2020Transasia Bio-Medicals, a leading Indian diagnostics company, announced the launch of india first high sensitivity test kit for Hepatitis C virus. Based on latest method, ErbaLisa HCV Gen 4 Ag+Ab kit, is india first and only 4th generation ELISA kit developed locally and has been evaluated by the National Institute of Biologicals (NIB). Additionally, the advancements in hepatitis C diagnostics are further contributing to the growth of the market. However, the high cost of hepatitis C testing may hamper the market growth.
The hepatitis C testing market is segmented on the basis of technique, test, end user and region. By technique, the market is fragmented into immunoassay, polymerase chain reaction (PCR) and others. The polymerase chain reaction (PCR) segment is further categorized into real-time PCR and other PCR.
According to the test, the market is categorized into antibody test, genotype tests, and viral load test. On the basis of end-user, the market is categorized into hospital and diagnostic laboratory, blood banks, and others. Region-wise, the market is analyzed through North America, Europe, Asia Pacificand LAMEA.
Key companies profiled in the report include Abbott Laboratories, BIO-RAD Laboratories Inc, Cosara Diagnostics Pvt Ltd, Illumina Inc, Meril Life Sciences Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., PerkinElmer, Qiagen NV, Thermo Fisher Scientific Inc and Trivitron Healthcare.
Main benefits for stakeholders
- This report provides a quantitative analysis of market segments, current trends, estimates and dynamics of Hepatitis C Testing Market analysis from 2021 to 2031 to identify current opportunities in the Hepatitis C Testing market Hepatitis C.
- Market research is offered with information related to key drivers, restraints, and opportunities.
- Porter’s Five Forces analysis highlights the ability of buyers and suppliers to enable stakeholders to make profit-driven business decisions and strengthen their supplier-buyer network.
- In-depth analysis of Hepatitis C Testing market segmentation helps to determine the existing market opportunities.
- Major countries in each region are mapped according to their revenue contribution in the global market.
- The positioning of market players facilitates benchmarking and provides a clear understanding of the current position of market players.
- The report includes analysis of regional and global Hepatitis C Testing market trends, key players, market segments, application areas and market growth strategies.
Main topics covered:
CHAPTER 1 INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
3.1. Definition and scope of the market
3.2. Main conclusions
3.2.1. The best investment pockets
3.3. Porter’s Five Forces Analysis
3.4. Positioning of the best player
3.5. Market dynamics
3.6. COVID-19 Market Impact Analysis
CHAPTER 4: HEPATITIS C SCREENING MARKET, BY TECHNIQUE
4.1.1 Market Size and Forecast
4.2.1 Key Market Trends, Growth Drivers and Opportunities
4.2.2 Market Size and Forecast, by Region
4.2.3 Market Analysis by Countries
4.3.1 Key Market Trends, Growth Drivers and Opportunities
4.3.2 Market Size and Forecast, by Region
4.3.3 Market Analysis by Countries
4.3.4 Hepatitis C PCR Testing Market by Type
126.96.36.199 Real-Time PCR Market Size and Forecast, by Region
188.8.131.52 Other PCR Market Size and Forecast, by Region
4.4 Other techniques
4.4.1 Key Market Trends, Growth Drivers and Opportunities
4.4.2 Market Size and Forecast, by Region
4.4.3 Market Analysis by Countries
CHAPTER 5: THE HEPATITIS C SCREENING MARKET, BY TEST
5.1.1 Market Size and Forecast
5.2 Antibody test
5.2.1 Key Market Trends, Growth Drivers and Opportunities
5.2.2 Market Size and Forecast, by Region
5.2.3 Market Analysis by Countries
5.3 Genotypic testing
5.3.1 Key Market Trends, Growth Drivers and Opportunities
5.3.2 Market Size and Forecast, by Region
5.3.3 Market Analysis by Countries
5.4 Viral load test
5.4.1 Key Market Trends, Growth Drivers and Opportunities
5.4.2 Market Size and Forecast, by Region
5.4.3 Market Analysis by Countries
CHAPTER 6: HEPATITIS C TESTING MARKET, BY END-USER
6.1.1 Market Size and Forecast
6.2 Hospital and diagnostic laboratory
6.2.1 Key Market Trends, Growth Drivers and Opportunities
6.2.2 Market Size and Forecast, by Region
6.2.3 Market Analysis by Countries
6.3 Blood banks
6.3.1 Key Market Trends, Growth Drivers and Opportunities
6.3.2 Market Size and Forecast, by Region
6.3.3 Market Analysis by Countries
6.4 Other end users
6.4.1 Key Market Trends, Growth Drivers and Opportunities
6.4.2 Market Size and Forecast, by Region
6.4.3 Market Analysis by Countries
CHAPTER 7: HEPATITIS C SCREENING MARKET, BY REGION
CHAPTER 8: CORPORATE LANDSCAPE
8.2. The best winning strategies
8.3. Top 10 Player Product Mapping
8.4. Competitive Dashboard
8.5. Competitive heatmap
8.6. Main developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Company Overview
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Commercial performance
9.1.6 Key strategic moves and developments
9.2 BIO-RAD Laboratories Inc.
9.2.1 Company Overview
9.2.2 Company Overview
9.2.3 Operating business segments
9.2.4 Product Portfolio
9.2.5 Commercial performance
9.2.6 Key Strategic Movements and Developments
9.3 Cosara Diagnostics Pvt Ltd
9.3.1 Company Overview
9.3.2 Company Overview
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Commercial performance
9.3.6 Key Strategic Movements and Developments
9.4 Illumina Inc.
9.4.1 Company Overview
9.4.2 Company Overview
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Commercial performance
9.4.6 Key strategic moves and developments
9.5 Meril Life Sciences Pvt. ltd.
9.5.1 Company Overview
9.5.2 Company Overview
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Commercial performance
9.5.6 Key strategic moves and developments
9.6 Molbio Diagnostics Pvt. ltd.
9.6.1 Company Overview
9.6.2 Company Overview
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Commercial performance
9.6.6 Key Strategic Movements and Developments
9.7 Perkin Elmer
9.7.1 Company Overview
9.7.2 Company Overview
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Commercial performance
9.7.6 Key Strategic Movements and Developments
9.8 Qiagen AG
9.8.1 Company Overview
9.8.2 Company Overview
9.8.3 Operating business segments
9.8.4 Product Portfolio
9.8.5 Commercial performance
9.8.6 Key strategic moves and developments
9.9 Thermo Fisher Scientific Inc.
9.9.1 Company Overview
9.9.2 Company Overview
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Commercial performance
9.9.6 Key strategic moves and developments
9.10 Trivitron Health
9.10.1 Company Overview
9.10.2 Company Overview
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Commercial performance
9.10.6 Key Strategic Movements and Developments
For more information about this report visit https://www.researchandmarkets.com/r/8l0xvd
Media Contact: Laura Wood | +353-1-481-1716 | [email protected]
SOURCE Research and Markets